Free Trial
NASDAQ:AVTE

Aerovate Therapeutics Q4 2024 Earnings Report

Aerovate Therapeutics logo
$12.48 +2.48 (+24.80%)
As of 05/2/2025

Aerovate Therapeutics EPS Results

Actual EPS
-$6.65
Consensus EPS
-$6.65
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Aerovate Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aerovate Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 27, 2025
Conference Call Time
1:00AM ET

Upcoming Earnings

Aerovate Therapeutics' Q2 2025 earnings is scheduled for Monday, May 12, 2025

Earnings Documents

Aerovate Therapeutics Earnings Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
See More Aerovate Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aerovate Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aerovate Therapeutics and other key companies, straight to your email.

About Aerovate Therapeutics

Aerovate Therapeutics (NASDAQ:AVTE), a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

View Aerovate Therapeutics Profile

More Earnings Resources from MarketBeat